Ideas to action: independent research for global prosperity
Search
Filters:
Experts
Facet Toggle
Topics
Facet Toggle
Content Type
Facet Toggle
Publication Type
Facet Toggle
Time Frame
Facet Toggle
Blog Post
January 10, 2023
Ahead of the holiday break, US lawmakers reached agreement on a final FY2023 spending deal. After months of stalled negotiations, an omnibus appropriations package was far from guaranteed. But concerns about the consequences of a long-term continuing resolution—and the prospect of adding a major tas...
Blog Post
December 15, 2022
Dr. Yi-Chun Lo of Taiwan’s Centers for Disease Control and National Taiwan University Hospital joins Javier Guzman to discuss Taiwan’s COVID-19 experience and broader pandemic preparedness and response efforts. Together, they discuss the lessons Taiwan learned from previous outbreaks like SARS, succ...
Multimedia
December 14, 2022
Dr. Yi-Chun Lo of Taiwan’s Centers for Disease Control and National Taiwan University Hospital joins Javier Guzman to discuss Taiwan’s COVID-19 experience and broader pandemic preparedness and response efforts. Together, they discuss the lessons Taiwan learned from previous outbreaks like SARS, succ...
Blog Post
December 14, 2022
As African and US Leaders meet in the Washington Summit this week, we decided to ask the leader of a key agency, with a long track record on the continent, how it is contributing to more effective and expanded US engagement. We asked Millennium Challenge Corporation (MCC) CEO Alice Albright a series...
CGD NOTES
December 14, 2022
Ensuring rapid and equitable access to effective oral COVID-19 therapies is essential to reducing health disparities from COVID-19 and building a better response system for future epidemics and pandemics. A multipronged strategy for medical countermeasures must include antivirals, monoclonal antibod...
Blog Post
December 14, 2022
It’s clear that COVID-19 oral antivirals are effective, and recent deals have made them even cheaper for African countries. But should these countries be investing in these medicines? Or would spending on alternative health services be better value for money? Unfortunately, there is very little avai...
CGD NOTES
December 14, 2022
Almost a year after two oral antiviral treatments received emergency use authorization, demand is extremely low. In this note, we argue that governments and their donor partners should use data and evidence to consider the economic and clinical rationale for registering, financing, purchasing, and d...
Blog Post
December 14, 2022
Four new CGD pieces, released today, examine the current state of play on COVID-19 oral antivirals. Our analyses provide a deep-dive in key cross-cutting areas—demand, voluntary licensing deals for generic supply, and deployment—and offer policy actions for 2023 and beyond.
Blog Post
December 07, 2022
How exactly should China's policymakers wade through competing models and guidance as it looks to ease its anti-COVID measures? This blog looks at how they should use models, using the case of the state of Hawaii; in sum, recommending that China’s National Health Commission take a thoughtful approac...